Rheumatoid arthritis: Time for trials of therapeutic targets

Journal of Rheumatology

Volumn 29, Issue 10, 2002, Pages 2041-2044

  Edmonds, John ^a   Lassere, Marissa ^a  

^a Department of Rheumatology ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; EDITORIAL; HUMAN; HYPERTENSION; MEDICAL EXAMINATION; MEDICAL RESEARCH; METATARSOPHALANGEAL JOINT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HEALTH STATUS; HUMANS; JOINTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 0036789750     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (24)

1. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
2. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000;343:1586-93.
4. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
5. Van de Putte LBA, Rau R, Breedveld FC, et al. One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl:S269.
6. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
7. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
8. World Health Organization-International Society of Hypertension. Guidelines Subcommittee. 1999 WHO-ISH guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
10. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
11. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75.
13. Furberg CD, Psaty BM, Pahor M, Alderman MH. Clinical implications of recent findings from the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) and other studies of hypertension. Ann Intern Med 2001;135:1074-8.
14. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001;135:1079-83.
15. Pinals RS, Masi AT, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
16. Wolfe F, Ross K, Hawley DJ, et al. The prognosis of RA and undifferentiated polyarthritis syndrome in the clinic: a study of 114 patients. J Rheumatol 1993;20:2005-9.
17. Suarez-Almazor M, Soskolne CL, Saunders LD, Russell AS. Outcome of RA. A 1985 inception cohort study. J Rheumatol 1994;21:1438-46.
18. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
19. van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
20. Spiegel TM, Spiegel JS, Paulus HE. The Joint Alignment and Motion Scale: A simple measure of joint deformity in patients with rheumatoid arthritis. J Rheumatol 1987;14:887-92.
21. Van der Heijde D, Lassere M, Edmonds J, et al. Minimal clinically important differences in plain films in RA: group discussions, conclusions and recommendations. J Rheumatol 2001;28:914-7.
22. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57:350-6.
23. Van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early RA. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
24. Boers M, Kostense PJ, Verhoeven AC, et al. Inflammation and damage in an individual joints predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 2001;44:2242-461.